| Code | CSB-RA006163MB18HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Zalifrelimab, targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA4), a critical immune checkpoint receptor expressed on T cells. CTLA4 functions as a negative regulator of T-cell activation by competing with CD28 for binding to B7 ligands (CD80/CD86) on antigen-presenting cells, thereby dampening immune responses and maintaining peripheral tolerance. Dysregulation of CTLA4-mediated immune suppression plays a significant role in cancer immune evasion, autoimmune diseases, and transplant rejection, making it a valuable target for immunotherapy research.
Zalifrelimab represents an investigational anti-CTLA4 antibody designed to enhance anti-tumor immunity by blocking CTLA4's inhibitory signals, thereby promoting T-cell activation and proliferation. This biosimilar antibody provides researchers with a reliable tool for studying CTLA4 biology, investigating immune checkpoint mechanisms, evaluating combination immunotherapy strategies, and exploring T-cell-mediated immune responses in various disease models. It serves as an essential reagent for immunology and oncology research programs focused on understanding and modulating adaptive immunity.
There are currently no reviews for this product.